A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease.

Trial Profile

A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
  • Indications Crohn's disease
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top